WO2012023623A3 - Agent pour le traitement du syndrome de hunter - Google Patents

Agent pour le traitement du syndrome de hunter Download PDF

Info

Publication number
WO2012023623A3
WO2012023623A3 PCT/JP2011/068815 JP2011068815W WO2012023623A3 WO 2012023623 A3 WO2012023623 A3 WO 2012023623A3 JP 2011068815 W JP2011068815 W JP 2011068815W WO 2012023623 A3 WO2012023623 A3 WO 2012023623A3
Authority
WO
WIPO (PCT)
Prior art keywords
hunter syndrome
treatment
agent
brain
sulphatase
Prior art date
Application number
PCT/JP2011/068815
Other languages
English (en)
Japanese (ja)
Other versions
WO2012023623A2 (fr
Inventor
義勝 衞藤
孝 樋口
十也 大橋
Original Assignee
日本ケミカルリサーチ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本ケミカルリサーチ株式会社 filed Critical 日本ケミカルリサーチ株式会社
Publication of WO2012023623A2 publication Critical patent/WO2012023623A2/fr
Publication of WO2012023623A3 publication Critical patent/WO2012023623A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour distribuer de l'iduronate-2-sulfatase humaine dans le cerveau d'un patient afin de prévenir la progression d'une lésion cérébrale chez des patients ayant le syndrome de Hunter. Le procédé est caractérisé en ce qu'un agent de traitement contenant de l'iduronate-2-sulfatase humaine est administré dans le cerveau d'un patient ayant le syndrome de Hunter.
PCT/JP2011/068815 2010-08-19 2011-08-15 Agent pour le traitement du syndrome de hunter WO2012023623A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-200310 2010-08-19
JP2010200310 2010-08-19

Publications (2)

Publication Number Publication Date
WO2012023623A2 WO2012023623A2 (fr) 2012-02-23
WO2012023623A3 true WO2012023623A3 (fr) 2012-04-12

Family

ID=45605484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/068815 WO2012023623A2 (fr) 2010-08-19 2011-08-15 Agent pour le traitement du syndrome de hunter

Country Status (2)

Country Link
JP (1) JP2012062312A (fr)
WO (1) WO2012023623A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
DK3103469T3 (en) 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
JP6045492B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
EP2793922B1 (fr) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Formulations stables pour l'administration au système nerveux central d'arylsulfatase a
EP3088518A4 (fr) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de transferrine qui traverse la barrière hémato-encéphalique
CA2990565A1 (fr) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain
MY187033A (en) 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
PE20181329A1 (es) 2015-12-30 2018-08-20 Green Cross Corp Metodos y composiciones para el tratamiento del sindrome de hunter
BR112019009316A2 (pt) 2016-12-26 2019-08-06 Japan Chem Res anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
US11117963B2 (en) 2016-12-26 2021-09-14 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
EP3816291A4 (fr) 2018-06-26 2022-03-16 Kyowa Kirin Co., Ltd. Anticorps se liant au protéoglycane-5 à chondroïtine sulfate
KR20210027295A (ko) 2018-06-26 2021-03-10 쿄와 기린 가부시키가이샤 세포 부착 분자3에 결합하는 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525963A (ja) * 2006-01-20 2009-07-16 ジェンザイム・コーポレーション リソソーム蓄積症のための脳室内酵素の輸送

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525963A (ja) * 2006-01-20 2009-07-16 ジェンザイム・コーポレーション リソソーム蓄積症のための脳室内酵素の輸送

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COOK, A.M. ET AL.: "Intracerebroventricular administration of drugs", PHARMACOTHERAPY, vol. 29, no. 7, 2009, pages 832 - 45, XP009147777, DOI: doi:10.1592/phco.29.7.832 *
IDENSHI KUMIKAE MUKO TATOSHO II-GATA CHIRYOZAI ELAPRASE TENTEKI SEICHUEKI 6MG TENPU BUNSHO, 2008 *
PAN, J. ET AL.: "Widespread correction of brain pathology in Hunter mice after an intracerebral injection of idursulfase", ACTA PAEDIATRICA, vol. 97, no. 457, 2008, pages 103 *
TAKASHI HIGUCHI ET AL.: "MPSII-gata Knockout Mouse de no Noshitsu Nai Koso Chiryo ni Kansuru Kenkyu", JAPANESE JOURNAL FOR INHERITED METABOLIC DISEASES, vol. 26, no. 2, 24 September 2010 (2010-09-24), pages 82 *

Also Published As

Publication number Publication date
WO2012023623A2 (fr) 2012-02-23
JP2012062312A (ja) 2012-03-29

Similar Documents

Publication Publication Date Title
WO2012023623A3 (fr) Agent pour le traitement du syndrome de hunter
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
ZA201400616B (en) Methods and devices for drug delivery to ocular tissue using microneedle
IL231657A0 (en) A system for transferring a cardiac graft through a wire to treat congestive heart failure and other conditions
IL221373A0 (en) System for determining treatment-related data for the administration of drugs to patients to be treated for the administration of drugs to patients to be treated taking into account important individual factors
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
EP3143997A3 (fr) Procedes d'administration d'une therapie par le pirfenidone
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
WO2014036556A3 (fr) Systèmes d'administration de médicaments et méthodes de traitement du cancer de la prostate
GB201008885D0 (en) Methods for administration and formulations for the treatment of reginal adipose tissue
EP2765971A4 (fr) Poche et procédé pour l'administration intraveineuse ou intracorporelle de solution médicale à un patient
WO2011133826A3 (fr) Méthode de traitement du cancer du pancréas
EP2424602A4 (fr) Procédé et système d'administration d'un agent de traitement dans la peau d'un patient
WO2011139867A3 (fr) Méthode de traitement du cancer du cerveau
EP2431049A4 (fr) Préparation pharmaceutique destinée à être administrée dans des organes respiratoires pour le traitement ou la prévention de maladies respiratoires inflammatoires, et procédé de traitement ou de prévention de telles maladies
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
EA032959B9 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
UA65038U (ru) Способ лечения больных послеродовыми психозами
AU2009901909A0 (en) A method and system for delivering a treatment agent into the skin of a patient
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
UA49567U (ru) Способ лечения хронических заболеваний кишечника у больных гипертонической болезнью

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11818263

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11818263

Country of ref document: EP

Kind code of ref document: A2